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Genomic instability and DNA replication defects in progeroid syndromes
Romina Burla a,b, Mattia La Torre a,b, Chiara Meriglianoa, Fiammetta Vernì a, and Isabella Saggio a,b,c
aDipartimento di Biologia e Biotecnologie “C. Darwin”, Sapienza Università di Roma, Roma, Italy; bIstituto di Biologia e Patologia Molecolari
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ABSTRACT
Progeroid syndromes induced by mutations in lamin A or in its interactors – named progeroid
laminopathies – are model systems for the dissection of the molecular pathways causing physio-
logical and premature aging. A large amount of data, based mainly on the Hutchinson Gilford
Progeria syndrome (HGPS), one of the best characterized progeroid laminopathy, has highlighted
the role of lamins in multiple DNA activities, including replication, repair, chromatin organization
and telomere function. On the other hand, the phenotypes generated by mutations affecting
genes directly acting on DNA function, as mutations in the helicases WRN and BLM or in the
polymerase polδ, share many of the traits of progeroid laminopathies. These evidences support
the hypothesis of a concerted implication of DNA function and lamins in aging. We focus here on
these aspects to contribute to the comprehension of the driving forces acting in progeroid
syndromes and premature aging.
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Progeroid syndromes are rare genetic diseases
characterized by reduced lifespan and by prema-
ture appearance of symptoms related to physiolo-
gical aging. For a majority of progeroid syndromes
the causative mutation has been identified point-
ing to the role of DNA function and of lamins in
these diseases. We report here on these syndromes,
on their genetics and on the molecular mechan-
isms involved in generating the related pheno-
types, focusing on the interrelationships between
lamins and DNA function.
Mutations affecting DNA function cause
progeroid syndromes
Given the direct connection between DNA function
and cell senescence and the implication of senes-
cence in aging[1], it is not surprising that many
progeroid syndromes are caused by mutations in
genes encoding for DNA repair and DNA mainte-
nance enzymes (Tables 1 and 2). These include the
Werner Syndrome caused by mutations in the DNA
helicase WRN[2], the Bloom Syndrome caused by
mutation in the helicase BLM [3], the Rothmund-
Thomson syndrome caused by mutations in the gene
RECQL4 [4], another DNA helicase, the Cockayne
syndrome involving either the ERCC8 or ERCC6
genes, that are implicated in DNA repair [5], the
Xeroderma pigmentosum also caused by mutations
in the DNA repair machinery elements [6], the
Dyskeratosis congenita involving genes implicated
in telomere function, including TERT, TERC and
DKC1 [7], and the mosaic variegated aneuploidy
syndrome caused by genes implicated in cell divi-
sion[8].
Mutations of nuclear envelope components
cause progeroid syndromes
Along with DNA function genes, a major genetic
cause of progeroid syndromes are mutations of
nuclear envelope factors or of their interactors [9],
which defines the group of progeroid laminopa-
thies. Differently from other premature aging syn-
dromes, progeroid laminopathies have early onset,
are usually pediatric diseases, and display more
severe symptoms of aging. Another feature that
distinguishes progeroid laminopathies from the
other premature aging syndromes, is the absence
of increased cancer susceptibility (Table 1).
The most characterized progeroid laminopathy
is Hutchinson Gilford Progeria syndrome (HGPS),
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Table 1. Progeroid syndromes caused by lamin and DNA function linked genes. The table highlights common
characteristics of genetically different progeroid syndromes. The colored map indicates that progeroid traits
are prevalently modulated in the same direction in progerias generated by either lamin (LMNA, ZMPSTE24) or
DNA function (POLD1, SPRTN, AKTIP) mutations. hm: homozygous; hz: heterozygous; AD: autosomic dominant;
AR: autosomic recessive; de novo: sporadic mutation; RJALS: Ruijs-Alfs syndrome; SCC: squamous cells
carcinoma; HCC: hepatocellular carcinoma; H: hypomorphic mutation; kof: knock out first; * model organism
mouse.
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HGPS 176670 LMNA p.G608G; p.G608S hz/ de novo
10, 11, 
13, 71
RD 275210 ZMPSTE24 
p.F361fsX379; 
p.W340X; 
p.I19-YfsX28; 
p.W340X; 
p.I198YfsX20+
p.F361fsX379 
hm/AR 
compound hz/AR
72,73
MADA 248370 LMNA 
p.R527H; 
p.M540I; 
p.A529T; 
p.A529V; 
p.R527H+ 
p.V440M; 
p.R471C+ 
R527C 
hm/AR 
compound hz/AR
25, 74-
81,51
MADB 608612 ZMPSTE24 
p.L94P; 
p.P248L+
p.W450X; 
p.P248L+ 
p.Q41X; 
p.F361fsX379+
p.W340R; 
p.F361fsX379+
p.N245S 
hm/AR 
compound hz/AR
82, 83,
84,85,
51
NGPS 614008 BANF1 p.A12T hm/AR 26, 27
APS - LMNA 
p.P4R hz/AD 86
p.T10I hz/de novo 86-88
p.G111K hz/de novo 86
p.D136H hz/AD 86, 89
p.E138K hz/de novo; AD 90,91
p.S143F hz/ de novo 92
p.E145K hz/de novo 11
p.G159K hz/de novo 86
p.V169fsX176 hz/de novo 35
p.R471C hm/AR 93
p.R527C hm/AR 94
p.T528M+ 
pM540T compound hz/AR
95
p.S573L hm/AR 96
p.E578V hz/de novo 88
p.C588R hz/de novo 86
p.R644C hz/de novo 88
(Continued )
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which is caused by a mutation in the LMNA gene
generating a mutant lamin A indicated as progerin
[10,11]. HGPS is an extremely rare, dominant
genetic disorder affecting 1 in 8 million live new-
borns, with a prevalence of 1 in 20 million living
individuals (The Progeria Research Foundation,
2018; https://www.progeriaresearch.org/prf-by-
the-numbers/). Children affected by HGPS show
severe growth retardation, alopecia, loss of
subcutaneous fat, prominent eyes and scalp veins,
thin skin, joint stiffness and reduced bone density.
They suffer from osteoporosis, atherosclerosis and
cardiovascular diseases, that finally cause their pre-
mature death at an average age of 14 years [12,13].
Patients with HGPS do not develop childhood
tumors, and progerin exerts a tumor-protective
function [9]. Along with this, cells from HGPS
show different aberrant phenotypes including
Table 1. (Continued).
p.T623S hz/de novo 34
APS or 
neonatal 
progeria 
- LMNA 
p.E55K hz/de novo 97
p.E55G hz/de novo 97
p.R435C hm/AR 98
AWS 150330 LMNA 
p.A57P hz/de novo 36
p.L59R hz/de novo 99
p.L59V hz/de novo 100
p.R133L hz/de novo 36
p.L140R hz/de novo 36
p.D300N hz/AD 101
p.D300G hz /AD SCC 102
MDPL 615381 POLD1 p.S605del; p.R507C hz/de novo 
67-69
RJALS 616200 SPRTN 
p.K241NfsX8; 
p.Y117C+ 
p.K239KfsX7 
hm/AR; 
 compound 
hz/AR 
HCC 61,103
- - Sprtn H/H transgenic mice * * * * * * * * * * * 62
- - AKTIP/Ft1 kof/kof transgenic mice * * * * * * * * * * * 63, 64
human mice 
  <1year 3≤weeks<20 affected 
  1≤ years>10 not affected 
  10≤ years >19 21≤weeks<60 not analyzed 
≥19years 60≤weeks<100 
Table 2. Dissection of DNA functions impaired in progeroid syndromes of different origins. Alterations in one or more of the DNA
functions, caused by mutations in the genes indicated, result in a premature aging phenotype. DC: Dyskeratosis congenita; WS:
Werner syndrome; BS: Bloom syndrome; R-TS: Rothmund-Thomson syndrome; CS: Cockayne syndrome; XP: Xeroderma pigmento-
sum. Nd: not determined.
DNA functions altered in progeroid syndromes
Disease
Altered
gene
Telomere
metabolism
Chromatin
remodeling
DNA
transcription
DNA
replication
DNA
repair References
HGPS, MADA, APS,
AWS
LMNA altered altered altered altered altered [15,23,29,50,104]
DC TERT/TERC altered nd nd nd nd [7]
DC DKC1 altered nd nd nd nd [7]
- AKTIP altered altered nd altered nd [63,65]
WS WRN altered altered altered altered altered [105–109]
BS BLM altered altered altered altered altered [110–113]
R-TS RECQL4 altered nd nd altered altered [109]
CS ERCC8/
ERCC6
nd nd nd nd altered [5]
RJALS SPRTN nd nd nd altered altered [62,114]
MDPL POLD1 nd nd nd altered altered [70]
XP XPA nd nd nd nd altered [31]
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misshapen nuclei and a disorganized nuclear
lamina and envelope [14], altered gene expression
[15], cellular senescence [16], genomic instability,
revealed by the persistent DNA damage response
activation and defects in the repair pathways
[17,18], impaired chromatin organization [19–21]
and abnormal telomere metabolism [22,23]. This
wide variety of aberrant phenotypic features likely
reflects the high number of different, and essential,
cellular processes in which lamin A is involved.
Restrictive Dermopathy (RD) is another exam-
ple of lamin related progeroid syndrome. Its cau-
sative mutations are found in the gene ZMPSTE24,
whose product is implicated in the maturation of
lamin A. RD clinical phenotype differs from HGPS
on that it is a perinatal lethal disease characterized
by a severe intrauterine growth delay. After birth,
affected children display a characteristic thin,
translucent, tight skin, and a typical facial dys-
morphism characterized by a small pinched nose,
micrognathia and mouth in a fixed ‘o’ shape. RD
patients suffer from joint contractures, respiratory
insufficiency in which the respiratory failure most
often leads to neonatal death within several weeks
of birth [24].
Along with HGPS and RD, nuclear envelope
related progerias include the Atypical Werner syn-
drome (AWS), the Atypical Progeria syndrome
(APS), the MandibuloAcral Dysplasia type A
(MADA), which have been all related to mutations
in LMNA, and MandibuloAcral Dysplasia type B
(MADB) which has been related to mutations in
ZMPSTE24. MADA is a less severe progeroid
laminopathy as compared to HGPS and RD. The
clinical features appear at 4 years of age and
become more severe with increasing age. This dis-
order is characterized by growth retardation, post-
natal onset of craniofacial anomalies with
mandibular hypoplasia, skeletal abnormalities
with progressive distal phalanges and clavicular
osteolysis. Some patients show progeroid features
such as thin nose, sparse, brittle hair, and sclero-
dermatous skin. Among other typical features
there are lipodystrophy and metabolic complica-
tions due to insulin resistance [25].
Another case of progeroid laminopathy, deser-
ving particular attention in relation with DNA
function, is the Nestor Guillermo Progeria syn-
drome (NGPS). NGPS is defined as chronic
progeria because it has a slow clinical course and
long survival despite its early onset. Patients dis-
play growth retardation, although less pronounced
than HGPS patients, micrognatia, lipoatrophy and
major skeletal deformation with severe osteoporo-
sis and osteolysis [12,26]. NGPS is caused by
mutations in BANF1 gene encoding for the bar-
rier-to-autointegration factor 1 (BAF1) protein.
BAF1 binds the nuclear lamina related LEM pro-
teins LAP2α, Emerin, and MAN1, and acts on
DNA function by binding chromatin and histones
[18,26,27]. NGPS is thus suggestive of a strong
connection between nuclear lamina and DNA
function in generating the progeroid phenotype.
isorder characterized by growth retardation, postnatal
onset of craniofacial anomalies with mandibular hypo-
plasia, skeletal abnorm alities with progressive distal
phalanges, and clavicular osteolysis, in addition to skin
changes like mottled pigmentati on and atrophy
[Young et al., 1971; Freidenberg et al., 1992; Tudisco
et al., 2000; Simha and Garg, 2002]. Some patients show
progeroid (premature aging) features such as thin nose,
sparse, brittle hair, and sclerodermatous (stiff and
parched) skin. Among other typical features we can
find lipodystrophy and metabolic complications due
to insulin resistance and diabete
Genomic instability is a common trait of
progeroid syndromes
Genomic instability is a trait of progeroid syn-
dromes deriving from both mutations in lamin
and in factors controlling DNA function, and is
emerging as driver of aging. In fact both physio-
logical and premature aging can be read as the
consequence of cell senescence, which, in turn is
generated by genomic damage.
Progerin expressing samples accumulate DNA
damage, which is highlighted by the presence of
intranuclear γH2AX positive foci that are induced
by DNA double strand breaks (DSBs). Foci
increase in number with continued passage and,
at the same time, cell growth rate slows down till
reaching premature senescence [28,29]. Along
with this, HGPS samples exhibit persistent DNA
damage checkpoint activation, including the phos-
phorylation of the DNA damage signaling element
ATM, the activation of the checkpoint regulators
Chk1 and Chk2 and that of the guardian of the
genome p53 [28,29]. Moreover, DNA repair is
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impaired in laminopathic cells. Fibroblasts from
HGPS patients and mouse embryonic fibroblasts
(MEFs) derived from progeroid models, such as
Zmpste24 knock out mice, are extremely sensitive
to genotoxic agents as camptothecin and etopo-
side, which are DSBs inducers, but also to UV
irradiation that typically activates the Nucleotide
Excision Repair (NER) pathway [30]. This
increased sensitivity is mechanistically explained
by the observation that laminopathic cells display
impaired recruitment of DNA repair proteins at
DSBs, which then remain unrepaired. Indeed, an
aberrant repair scheme has been observed in
HGPS cells, characterized by delayed or inefficient
recruitment of the DNA damage response factor
53BP1, of the Non Homologous End Joining
(NHEJ) repair protein Ku70 and of the
Homology directed repair (HDR) elements
Rad50, Rad51, and by aberrant sequestration of
the NER component XPA [31] at DSBs. These
alterations block the correct DSB repair sequence
and cause general impairment of NER [32].
Altered protein-protein interaction bridges
DNA function to nuclear envelope in
progeroid syndromes
HGPS patients present de novo mutations in exon
11 of LMNA gene leading to the activation of a
cryptic splice site that brings to the synthesis of
progerin. Progerin does not contain the lamin A
cleavage site for Zmpste24, for this reason the
protein does not undergo the final step of proces-
sing, giving rise to a permanently farnesylated
mutant protein. In a subset of progeroid lamino-
pathies, in MADB and RD for example, the disease
is caused by compound heterozygous and homo-
zygous mutations in FACE1 gene that encodes for
Zmpste24. The mutations give rise to defective
protein activity, total loss of function in RD, and
lead to the accumulation of a prelamin A form
that is not properly processed and retains the
farnesylated C-terminus.
These results have suggested the idea that dif-
ferent progerias share a common functional cause
in the accumulation of mutant forms of perma-
nently farnesylated lamin A, that could be toxic for
the cell. Based on this assumption, therapeutic
approaches for progerias have been focused on
drugs inhibiting the farnesylation of progerin and
prelamin A, including lonafarnib, pravastatin and
zoledronic acid [33]. However, the recent identifi-
cation of progeroid clinical phenotypes not related
to the accumulation of farnesylated lamin A have
highlighted that this is not the full explanation for
the cellular defects observed in these diseases.
Indeed, for example, the majority of APS and
AWS cases are caused by different mutations in
exons of LMNA gene, that do not give rise to splice
variants of the protein generating the accumula-
tion of farnesylated products, but are nonetheless
characterized by a progeroid phenotype. There are
exceptions in which APS and AWS are linked to
mutations causing both amino acid changes and
the formation of truncated versions of lamin A,
that theoretically could remain farnesylated
[34,35]. However, its not clear if they contribute
to phenotype and amino acid changes seem more
important, at least in one case [36], for the patho-
logical phenotype. Along with this, the identifica-
tion of the causative mutation of NGPS in BANF1
has further underlined that progeroid laminopa-
thies do not necessarily arise from the accumula-
tion of toxic farnesylated mutant lamin A [18].
Accordingly, cell treatments with farnesyltransfer-
ase inhibitors, used to treat HGPS patients, revert
only some phenotypic aberrant cellular traits, such
as nuclear misshapen, but not all of them. For
example, they do not avoid senescence or DNA
damage activation in HGPS cells [28]. The same
result was obtained by in vivo studies. The treat-
ment with farnesyltransferase inhibitors of two
progeria mouse models, ZMPSTE24-deficient
mice and LMNAHG/+ knock in mice, ameliorates
the disease phenotype but not completely, and all
treated mice eventually develop severe phenotypes
and prematurely die [37–39].
Further evidence supporting the idea that per-
manent farnesylation is not the only driver in
progeria, is the recent finding that a mutant pro-
gerin, which is not farnesylated as in HGPS, when
expressed in normal cells fully mimics HGPS pro-
gerin in its ability to promote senescence [40].
Similar results were obtained also in vivo, in a
mouse model expressing a non-farnesylated ver-
sion of progerin, LMNAnHG/+, in which the
cysteine of the CaaX motif was replaced with a
serine. These animals develop the disease
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phenotype, although in a milder form if compared
to mice expressing farnesylated progerin [38]. The
same group reported a second mouse model
expressing a different progerin, LMNAcsmHG/+,
that cannot be farnesylated as well, in which a
total disease recovery was observed [41], indicating
that, actually, which is the importance of perma-
nent farnesylated products in generating pathology
is not yet fully clarified.
Altered protein-protein interaction and protein
mislocalization or sequestration are now proposed
as the origin for the multiplicity of phenotypic
traits of progeroid laminopathies. The hypothesis
is that an organized lamin A network is necessary
for coordinating cellular processes through the
formation of macrocomplexes including specific
partners. Mutant lamin A networks create abnor-
mal interactions of proteins that act in DNA func-
tion, which, in turn, impinges on their correct
activity [12,40,42,43]. This hypothesis rests on the
discovery that lamin A mutants and, in particular,
progerin, differentially interact with a subset of
lamin A interacting proteins, and this could
account for the deregulation of important cellular
processes coordinated by lamins [43–46]. For
example, progerin shows an altered interaction
with transcription factors including Prx1 and
Ing1. It induces their mislocalization and this con-
tributes to the HGPS phenotype [15,46,47].
Progerin was also proven to be unable to interact
with members of NURD chromatin remodeling
complex, which was shown to contribute to chro-
matin defects observed in HGPS [21]. Differential
interactions of progeroid cells were also observed
for DNA repair proteins. Among these, DNA-
PKcs, Ku80 and Ku70[48], which interact with
lamin A, lose their interaction with progerin.
This result indicates that lamin A is functional to
the maintenance of a nucleoplasmic pool of DNA
repair proteins, which is expected to facilitate their
rapid recruitment to sites of DNA damage. The
inability of progerin to bind them causes DNA
repair impairment, leading to genomic instability
[48]. Recently it was demonstrated that progerin
interacts preferentially with a pivotal element of
the DNA replication machinery, the proliferating
cell nuclear antigen (PCNA), which clamps DNA
at the forks and favors the processivity of DNA
replication [49]. Differently from wild type lamin
A, progerin sequesters PCNA far away from repli-
cative forks, causing fork stalling and consequent
DNA damage [40,50]. PCNA mislocalization,
altering proper DNA replication, accounts for
multiple cellular defects of progeroid cells includ-
ing persistent DNA repair activation and genomic
instability [40,50].
The accumulation of different forms, both non
farnesylated and farnesylated, of prelamin A, a
part from progerin, to toxic level is associated to
MADA, MADB and RD progeroid laminopathies
and has been also reported in association with
cellular stress and senescence [51]. Recent studies
analyzing the molecular basis of prelamin
A-related chromatin organization changes
observed in patients cells, further support the
idea that aberrant lamin A could create abnormal
interactions of proteins that could affect genome
stability. Indeed it was demonstrated that BAF1
interacts preferentially with prelamin A rather
than with mature lamin A and this interaction
affects BAF1 cellular localization inducing its
nuclear retention when prelamin A is abnormally
accumulated. This, in turn, induces mislocalization
of other chromatin remodeling factors altering the
chromatin status [52]. Moreover prelamin A-BAF1
interaction is compromised by the BANF1 gene
mutation occurring in NGPS and this could
account, at least in part, to the pathological cellular
phenotype [53]. Prelamin A is also able to interact
with PCNA better than mature lamin A. Indeed, it
was demonstrated that the presence of prelamin A
interferes with DNA replication fork stability by
sequestering PCNA away from its canonical inter-
action with lamin A [54].
These studies taken together indicate that pro-
geroid defects are not only linked to farnesylation,
but also to the alteration of macrocomplex forma-
tion caused by dysfunctional lamin A.
DNA replication is altered in progeroid
syndromes
Different lines of evidence support the hypoth-
esis that a prominent source of DNA damage in
progeroid samples is DNA replication impair-
ment. It has been observed that in patients’
HGPS cells and in ectopically expressing pro-
gerin cells the S-phase is prolonged, and DNA
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damage occurs predominantly during this phase
[40]. Moreover, γH2AX foci were identified as
co-localizing with phospho-RPA32 (Ser33),
which is a marker of DNA replication stalled
forks [50]. It was also assessed that DNA
damage foci are positive for MCM7, which is a
component of the DNA replication complex,
remaining on site when forks are stalled or col-
lapsed. Finally, as anticipated above, DNA repli-
cation impairment in HGPS has been linked to
PCNA activity. More specifically, it has been
demonstrated that progerin sequesters PCNA,
creating PCNA positive intracellular aggregates
which localize away from replicating DNA, this
causes processivity defects, indicated by the
decreased rate of replication fork progression
observed in HGPS cells, along with replication
stress and consequent DSBs formation [40,50].
Several groups have focused on the molecular
dissection of the link between lamins and DNA
replication. A first elementary aspect underlining
this connection is that lamins are present at
replication sites early in S-phase. Another direct
relation is that lamins interact with DNA polδ
and ε [55]. Moreover, A-type lamins are
required for the elongation stage of replication
[56,57]. In fact, the disruption of the lamina,
obtained by using a dominant negative lamin A
mutant, induces not only the mislocalization of
PCNA but also that of the Replication Factor C
(RFC) complex, which as PCNA, is essential for
the elongation phase of DNA replication [56,57].
A-type lamins are also required for the resolu-
tion of stalled replication forks [58]. Lamin A/C
depleted cells are indeed unable to restart forks
after a replication stress resulting in shorter
track length and in the formation of chromoso-
mal aberrations [58]. Biochemical evidences
further support the link between lamins and
the replication machinery. In fact, a direct inter-
action between lamins and PCNA occurs
through their highly conserved Ig-fold domain
and this interaction is important for PCNA posi-
tioning on chromatin [59].
The relation between DNA replication and pro-
gerias is supported also from studies of progeroid
syndromes caused by mutations in DNA replica-
tion genes. For example, mutations in SPRTN,
encoding the PCNA interacting protein Spartan,
with a role in the error-prone translesional DNA
synthesis (TLS) [60], were identified in three AWS
patients [61]. Spartan dysfunction leads to sus-
tained DNA replication stress characterized by
decreased DNA replication fork progression
speed, incomplete DNA replication and impaired
lesion bypass. These replication defects cause DNA
damage that, in turn, induces aging or cancer, due
to a leakage of G2/M checkpoint observed in cells
from these patients [61,62]. Mice bearing hypo-
morphic alleles of SPRTN are growth retarded,
show lipodistrophy, develop cataracts, lordoky-
phosis and cachexia at a young age [62]. This
phenotype recalls those of other progeria models.
We observed progeroid traits in a mouse model
defective in a gene implicated in DNA function
named AKTIP (in humans and Ft1 in mouse)
[63–65]. We described that AKTIP dysfunction
causes DNA replication and telomere defects,
which in turn generate DNA damage activation
and cell senescence [63]. Consistently with the con-
nection of AKTIP both with lamins and DNA
function, hypomorphic mice (Ft1kof/kof, Ft1 Knock
out first) displayed premature aging defects, includ-
ing reduced body size, lipodistrophy, altered bone
density and kyphosis [64]. We demonstrated that
the phenotype is partly rescued by co-depletion of
p53, pointing to the interplay between DNA
damage and progeria. We also defined that AKTIP
binds to the replication factors PCNA and RPA70,
altogether falling into the triangular connection
described here among lamins, progerias and DNA
function [65].
A further link between DNA function and
lamins comes from studies on mutation of
POLD1. Heterozygous mutations in POLD1 have
been found in patients with Mandibular hypopla-
sia displaying Deafness, Progeroid features and
Lipodystrophy (MDPL) [66–69]. POLD1 encodes
for the catalytic subunit, called p125 subunit or A
unit, of polδ, the polymerase responsible for DNA
lagging synthesis also involved in DNA repair [70].
Polδ has been shown to interact with lamin A/C in
early S-phase [55]. Currently it is not known
which is the impact of POLD1 mutations at mole-
cular level, but it was suggested that heterozygous
mutant POLD1 leads to increased numbers of
stalled replication forks, which would then trigger
cellular senescence [68].
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Concluding remarks
Despite the rarity of progeroid syndromes,
researches aimed at the understanding of the
molecular pathways involved in these diseases are
important, not only to find new therapeutic
approaches, but also to understand the mechan-
isms leading to physiological aging. Among pro-
geroid laminopathies the most widely studied is
HGPS, caused by mutations leading to accumula-
tion of aberrant lamin A that induces a wide range
of pathological phenotypes, both at organismal
and cellular level. In HGPS and other laminopa-
thies the large array of aberrant phenotypes
reflects the fact that lamins coordinate a variety
of fundamental molecular mechanisms, ranging
from chromatin organization and regulation, to
nuclear structural organization and functioning.
The pathogenic molecular mechanism of HGPS
was initially attributed to the presence of the far-
nesyl group in progerin. For this reason therapeu-
tic approaches have aimed at blocking progerin
farnesylation. Recently, however, a further impor-
tant interpretation has emerged from studies on
progerias. The hypothesis is that mutated lamins
interact differently with their partners creating an
aberrant intranuclear macrocomplex scenario.
Central processes are affected by this intranuclear
misorganization including, importantly, DNA
replication and repair. Many players are involved
in this aberrant picture, including the DNA pro-
cessivity factor PCNA.
The identification of DNA replication and
genomic instability as drivers of the premature
aging phenotype in HGPS and other progeroid
diseases will help identifying new therapeutic
approaches for these devastating pathologies. In
addition, considering that progeroid syndromes
recapitulate aspects of physiological aging, the dis-
section of the mediators of the disease phenotype
will also give hints into the coveted comprehen-
sion of the complex, multifaceted process of aging
in humans.
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